Maria R. Zocchi

Milan, 20162, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 47 publications

The Role of LAIR1 as a Regulatory Receptor of Antitumor Immune Cell Responses and Tumor Cell Growth and Expansion.

The Role of LAIR1 as a Regulatory Receptor of Antitumor Immune Cell Responses and Tumor Cell Growth and Expansion.

Journal: Biomolecules
Published: April 22, 2025

Epidermal Growth Factor Receptor Targeting in Colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance.

Epidermal Growth Factor Receptor Targeting in Colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance.

Journal: International journal of molecular sciences
Published: June 05, 2024

Antibody-Drug Conjugate Made of Zoledronic Acid and the Anti-CD30 Brentuximab-Vedotin Exert Anti-Lymphoma and Immunostimulating Effects.

Antibody-Drug Conjugate Made of Zoledronic Acid and the Anti-CD30 Brentuximab-Vedotin Exert Anti-Lymphoma and Immunostimulating Effects.

Journal: Cells
Published: April 26, 2024

Immune Checkpoint Receptor/Ligand Expression and Chemotherapy in Colorectal Cancer.

Immune Checkpoint Receptor/Ligand Expression and Chemotherapy in Colorectal Cancer.

Journal: Cancers
Published: January 12, 2023

Evolution of 3D Cultures: Toward Tailored Preclinical Models.

Evolution of 3D Cultures: Toward Tailored Preclinical Models.

Journal: Cancers
Published: January 10, 2023

The Stockholm Syndrome of Cancer: Fibroblasts as a Powerful Shield against Colorectal Cancer Therapy.

The Stockholm Syndrome of Cancer: Fibroblasts as a Powerful Shield against Colorectal Cancer Therapy.

Journal: Cancers
Published: December 20, 2022

Priming of Colorectal Tumor-Associated Fibroblasts with Zoledronic Acid Conjugated to the Anti-Epidermal Growth Factor Receptor Antibody Cetuximab Elicits Anti-Tumor Vδ2 T Lymphocytes.

Priming of Colorectal Tumor-Associated Fibroblasts with Zoledronic Acid Conjugated to the Anti-Epidermal Growth Factor Receptor Antibody Cetuximab Elicits Anti-Tumor Vδ2 T Lymphocytes.

Journal: Cancers
Published: December 19, 2022

Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab.

Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab.

Journal: Journal for immunotherapy of cancer
Published: October 17, 2022

Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges.

Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges.

Journal: Molecular therapy oncolytics
Published: January 03, 2022

Lysyl-Oxidase Dependent Extracellular Matrix Stiffness in Hodgkin Lymphomas: Mechanical and Topographical Evidence.

Lysyl-Oxidase Dependent Extracellular Matrix Stiffness in Hodgkin Lymphomas: Mechanical and Topographical Evidence.

Journal: Cancers
Published: November 20, 2021

Three-Dimensional Culture Models to Study Innate Anti-Tumor Immune Response: Advantages and Disadvantages.

Three-Dimensional Culture Models to Study Innate Anti-Tumor Immune Response: Advantages and Disadvantages.

Journal: Cancers
Published: June 07, 2021

ADAM10 Site-Dependent Biology: Keeping Control of a Pervasive Protease.

ADAM10 Site-Dependent Biology: Keeping Control of a Pervasive Protease.

Journal: International journal of molecular sciences
Published: April 18, 2021
Showing 1-12 of 47

Last Updated: 09/26/2026